• Loading stock data...
Est. 2004

LEVERAGE OUR MASSIVE INVESTOR AUDIENCE!

Stock Investors · Accredited Investors · Hedge Fund Investors

Learn More

Sunday 04/22/2018
SMALL CAP MARKET NEWS

We release small market news updates daily, 5 times a week! Always check back to get the inside scoop on what going on.


LEVERAGE OUR MASSIVE INVESTOR AUDIENCE!

Stock Investors · Accredited Investors · Hedge Fund Investors

Learn More

Corporate Consultancy

  • 12:09 PM

    DUBAI, UAE, April 02, 2018 (GLOBE NEWSWIRE) — Argentum 47, Inc. ( www.arg47.com ), formerly known as Global Equity International, Inc., (OTC Pink: ARGQ) and its fully-owned foreign subsidiaries, a specialist in both Retail and Corporate Financial Services, Corporate Consultancy and Human Resources, with offices located in Dubai and the United Kingdom, is proud to announce that its plans to completely rebrand the Company are now in full effect. This rebranding comes as a result of management’s plans to completely change the Company’s direction by

    Read more
  • 3:06 PM

    Company is Currently Preparing IND for New Cancer Immuno-Therapy Drug SAN DIEGO, February 24, 2016, RGBP /PRNewswire/ — Regen BioPharma, Inc., (OTCBB: RGBP) and (PINK: RGBP) announced today completion of experiments, in collaboration with Dr. Santosh Kesari, demonstrating immunological mechanisms of its novel NR2F6 gene silencing approach. Subsequent to these experiments, the Company has begun the process of compiling an Investigational New Drug Application (IND) with the FDA for testing of this approach in cancer patients. Dr. Kesari is Director

    Read more
  • 4:09 PM

    SAN DIEGO, January 26, 2016, RGBP,/PRNewswire/ — Regen BioPharma, Inc., (OTCBB: RGBP) and (PINK: RGBP)   announced today submission to the Food and Drug Administration (FDA) of an application requesting Orphan Drug status for the use of HemaXellerate for the treatment of aplastic anemia. “Because HemaXellerate is a personalized cell therapy product aimed at addressing an unmet medical need, we are hopeful that the FDA will grant it orphan status,” said David Koos, Ph.D., Chairman and CEO of Regen BioPharma. HemaXellerate

    Read more
  • 1:23 PM

    HACKENSACK, N.J. and PETACH TIKVAH, Israel, June 29, 2015 /PRNewswire/ — BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, today announced that has been added to the Russell Microcap® Index.  The Russell indexes are reconstituted on an annual basis, with this year’s process having concluded on June 26.  Information on the Russell Microcap® Index and the reconstitution process can be found on the FTSE Russell website (http://www.russell.com/). “We are pleased to be added

    Read more
  • 4:27 PM

    EATONTOWN, Apr 09, 2014 (GLOBE NEWSWIRE via COMTEX) — American CryoStem Corporation (OTCQB:CRYO), a leading biotechnology developer and global licensor of patented adipose tissue-based adult stem cell technologies, today announced that the Company has been selected as an “Incubator Company of the Year” by the New Jersey Incubation Network (“NJBIN”). The award will be presented at NJBIN’s upcoming Second Annual Business Incubation Awards to be held on April 25, 2014 at the EcoComplex – Rutgers University’s Alternative Energy Innovation and

    Read more
Public Wire Banner